Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis
- PMID: 15329425
- DOI: 10.1056/NEJMoa033114
Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis
Abstract
Background: No safe and convenient regimen has proved to be effective for the management of recurrent vulvovaginal candidiasis.
Methods: After inducing clinical remission with open-label fluconazole given in three 150-mg doses at 72-hour intervals, we randomly assigned 387 women with recurrent vulvovaginal candidiasis to receive treatment with fluconazole (150 mg) or placebo weekly for six months, followed by six months of observation without therapy. The primary outcome measure was the proportion of women in clinical remission at the end of the first six-month period. Secondary efficacy measures were the clinical outcome at 12 months, vaginal mycologic status, and time to recurrence on the basis of Kaplan-Meier analysis.
Results: Weekly treatment with fluconazole was effective in preventing symptomatic vulvovaginal candidiasis. The proportions of women who remained disease-free at 6, 9, and 12 months in the fluconazole group were 90.8 percent, 73.2 percent, and 42.9 percent, as compared with 35.9 percent, 27.8 percent, and 21.9 percent, respectively, in the placebo group (P< 0.001). The median time to clinical recurrence in the fluconazole group was 10.2 months, as compared with 4.0 months in the placebo group (P<0.001). There was no evidence of fluconazole resistance in isolates of Candida albicans or of superinfection with C. glabrata. Fluconazole was discontinued in one patient because of headache.
Conclusions: Long-term weekly treatment with fluconazole can reduce the rate of recurrence of symptomatic vulvovaginal candidiasis. However, a long-term cure remains difficult to achieve.
Copyright 2004 Massachusetts Medical Society
Comment in
-
Chronic vulvovaginal candidiasis.N Engl J Med. 2004 Aug 26;351(9):851-2. doi: 10.1056/NEJMp048152. N Engl J Med. 2004. PMID: 15329419 No abstract available.
-
Chronic vulvovaginal candidiasis.N Engl J Med. 2004 Dec 9;351(24):2554-6; author reply 2554-6. doi: 10.1056/NEJM200412093512419. N Engl J Med. 2004. PMID: 15590964 No abstract available.
-
Chronic vulvovaginal candidiasis.N Engl J Med. 2004 Dec 9;351(24):2554-6; author reply 2554-6. N Engl J Med. 2004. PMID: 15599956 No abstract available.
-
Fluconazole reduced the rate of recurrence of vulvovaginal candidiasis.Evid Based Nurs. 2005 Apr;8(2):49. doi: 10.1136/ebn.8.2.49. Evid Based Nurs. 2005. PMID: 15830422 No abstract available.
Similar articles
-
[Treatment of recurrent vulvovaginal candidosis with mycosyst (fluconazole)].Akush Ginekol (Sofiia). 2005;44 Suppl 2:25-7. Akush Ginekol (Sofiia). 2005. PMID: 16028400 Bulgarian.
-
Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial).Am J Obstet Gynecol. 2008 Dec;199(6):613.e1-9. doi: 10.1016/j.ajog.2008.06.029. Epub 2008 Oct 30. Am J Obstet Gynecol. 2008. PMID: 18976735
-
Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis.Diabetes Care. 2007 Feb;30(2):312-7. doi: 10.2337/dc06-1469. Diabetes Care. 2007. PMID: 17259500 Clinical Trial.
-
Treatment of recurrent vulvovaginal candidiasis.Am Fam Physician. 2000 Jun 1;61(11):3306-12, 3317. Am Fam Physician. 2000. PMID: 10865926 Review.
-
Recurrent vulvovaginal candidiasis.Mo Med. 2006 Mar-Apr;103(2):165-8. Mo Med. 2006. PMID: 16703718 Review.
Cited by
-
Bacillus coagulans LMG S-24828 Impairs Candida Virulence and Protects Vaginal Epithelial Cells against Candida Infection In Vitro.Microorganisms. 2024 Aug 10;12(8):1634. doi: 10.3390/microorganisms12081634. Microorganisms. 2024. PMID: 39203476 Free PMC article.
-
The Role of Probiotics in the Treatment of Vulvovaginal Candidiasis: A Systematic Review and Meta-Analysis.Ethiop J Health Sci. 2023 Sep;33(5):881-890. doi: 10.4314/ejhs.v33i5.18. Ethiop J Health Sci. 2023. PMID: 38784519 Free PMC article. Review.
-
Vaginal microbiota: Potential targets for vulvovaginal candidiasis infection.Heliyon. 2024 Mar 2;10(5):e27239. doi: 10.1016/j.heliyon.2024.e27239. eCollection 2024 Mar 15. Heliyon. 2024. PMID: 38463778 Free PMC article. Review.
-
Bacterial Vaginosis and Vulvovaginal Candidiasis Pathophysiologic Interrelationship.Microorganisms. 2024 Jan 5;12(1):108. doi: 10.3390/microorganisms12010108. Microorganisms. 2024. PMID: 38257934 Free PMC article. Review.
-
Oteseconazole versus fluconazole for the treatment of severe vulvovaginal candidiasis: a multicenter, randomized, double-blinded, phase 3 trial.Antimicrob Agents Chemother. 2024 Jan 10;68(1):e0077823. doi: 10.1128/aac.00778-23. Epub 2023 Dec 14. Antimicrob Agents Chemother. 2024. PMID: 38095426 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources